

March 13, 2023

Baxter Update on U.S. INFUVITE Supply

On February 24, 2023, Baxter announced an outage for all INFUVITE Multiple Vitamins for infusion product configurations that are manufactured and supplied by a third-party manufacturer.

Currently, we have confirmation from our third-party manufacturer that we are able to release limited amounts of INFUVITE product.

What does this mean?

Customers who have backorders should start receiving INFUVITE beginning the week of March 13. While product availability is improving, please note that intermittent backorders are likely to continue through April.

To support balanced access to all facilities and patients in need of INFUVITE, a protective 100% allocation has been placed on the critical Pediatric Single Dose product code, and INFUVITE Adult Single dose will remain on 100% allocation. Please see below for details.

Product Description	Product Code	NDC	Allocation
INFUVITE Pediatric, Multiple Vitamins for infusion. Single dose Package, Contains 5 each of Vial 1 (4mL) and Vial 2 (1 mL)	2A9008	05464-3564-61	100%
INFUVITE Adult, Multiple Vitamins for infusion. Single dose Package, Contains 5 each of Vial 1 (5 mL) and Vial 2 (5 mL)	2A9018	05464-3564-91	100%

Is the INFUVITE formulation different?

No, INFUVITE product formulations remain exactly the same.

As there are currently no alternatives for INFUVITE available in the United States, we remain committed to helping providers minimize the impact of this situation for patients. As supply is reestablished, we continue to recommend that each patient be evaluated regarding the medical need for parenteral vitamins. Refer to ASPEN's "2021 Parenteral Nutrition Multivitamin Product Shortage Considerations" document for additional guidance. The document can be accessed at www.nutritioncare.org or by clicking here. Our U.S. Medical Affairs team are available for questions at medinfo@baxter.com.

We appreciate your patience and partnership as we navigate this challenging situation.

Mary Henson

General Manager, U.S. Commercial

Baxter Healthcare Corporation

May Henn

Brad Glazer, PharmD

Vice President, Medical Affairs, Americas

Baxter Healthcare Corporation